Pharsight

1. Alimta patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP01948214A	2012-10-30	Actavis Deutschland GmbH & Co. KG	Opposition rejected
EP01948214A	2008-01-17	Teva Pharmaceutical Industries Ltd.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7772209	July, 2016	FWD Entered	Eli Lilly and Company	Apotex Inc.
US7772209	July, 2016	FWD Entered	Eli Lilly and Company	Wockhardt Bio AG
US7772209	July, 2016	FWD Entered	Eli Lilly and Company	Teva Pharmaceuticals USA, Inc.
US7772209	July, 2016	FWD Entered	Eli Lilly and Company	Apotex Inc.
US7772209	June, 2016	FWD Entered	Eli Lilly and Company	Wockhardt Bio AG
US7772209	December, 2015	FWD Entered	Eli Lilly and Company	Sandoz Inc.
US7772209	November, 2015	FWD Entered	Eli Lilly and Company	Neptune Generics, LLC
US7772209	June, 2013	Terminated-Denied	Eli Lilly and Company	Accord Healthcare, Inc., USA

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5344932	LILLY	N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives	Jul, 2016 (7 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5344932 (Pediatric)	LILLY	N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives	Jan, 2017 (7 years ago)
US7772209	LILLY	Antifolate combination therapies	Nov, 2021 (2 years ago)
US7772209 (Pediatric)	LILLY	Antifolate combination therapies	May, 2022 (1 year, 10 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-571)	Sep 26, 2011
New Indication(I-601)	Jul 02, 2012
M(M-122)	Oct 17, 2015
M(M-61)	Mar 17, 2014
Pediatric Exclusivity(PED)	Sep 17, 2014

Drugs and Companies using PEMETREXED DISODIUM ingredient

Market Authorisation Date: 07 September, 2007

Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration

Dosage: POWDER;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
100 mg/vial	01 Jul, 2008	1	24 Jan, 2017	Extinguished
500 mg/vial	04 Feb, 2008	2	24 Jan, 2017	Extinguished
1000 mg/vial	27 Jun, 2012	1	24 Nov, 2021	Extinguished
750 mg/vial	06 Oct, 2016	1	24 Nov, 2021	Extinguished

Strength	Dosage	Availability
EQ 500MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 100MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

ALIMTA family patents

2. Cialis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5859006	LILLY	Tetracyclic derivatives; process of preparation and use	Nov, 2017 (6 years ago)
US6821975	LILLY	Beta-carboline drug products	Nov, 2020 (3 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6140329	LILLY	Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence	Jul, 2016 (7 years ago)
US5859006 (Pediatric)	LILLY	Tetracyclic derivatives; process of preparation and use	May, 2018 (5 years ago)
US6943166	LILLY	Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction	Apr, 2020 (3 years ago)
US7182958	LILLY	β-carboline pharmaceutical compositions	Apr, 2020 (3 years ago)
US7182958 (Pediatric)	LILLY	β-carboline pharmaceutical compositions	Oct, 2020 (3 years ago)
US6943166 (Pediatric)	LILLY	Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction	Oct, 2020 (3 years ago)
US6821975 (Pediatric)	LILLY	Beta-carboline drug products	May, 2021 (2 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-219)	Feb 15, 2021
Pediatric Exclusivity(PED)	Aug 15, 2021
New Indication(I-642)	Oct 06, 2014
New Indication(I-641)	Oct 06, 2014

Drugs and Companies using TADALAFIL ingredient

Market Authorisation Date: 07 January, 2008

Treatment: Treatment of erectile dysfunction; Treatment of sexual dysfunction

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg	14 Oct, 2008	1	22 May, 2018	19 Nov, 2020	Eligible
5 mg, 10 mg and 20 mg	21 Nov, 2007	1	22 May, 2018	19 Nov, 2020	Eligible

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

CIALIS family patents

3. Cymbalta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5023269	LILLY	3-aryloxy-3-substituted propanamines	Jun, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5023269 (Pediatric)	LILLY	3-aryloxy-3-substituted propanamines	Dec, 2013 (10 years ago)
US5508276	LILLY	Duloxetine enteric pellets	Jul, 2014 (9 years ago)
US5508276 (Pediatric)	LILLY	Duloxetine enteric pellets	Jan, 2015 (9 years ago)
US6596756	LILLY	Treatment of fibromyalgia	Sep, 2019 (4 years ago)
US6596756 (Pediatric)	LILLY	Treatment of fibromyalgia	Mar, 2020 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Apr 20, 2023
M(M-61)	Oct 18, 2015
New Indication(I-632)	Nov 04, 2013
Pediatric Exclusivity(PED)	May 04, 2014
New Indication(I-617)	Nov 19, 2012

Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 August, 2004

Treatment: Management of fibromyalgia (fm); Treatment of major depressive disorder(mdd); Although the mechanism of the antidepressant action of duloxetine in humans is unknown, it is believed to be related to it...

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 30 mg and 60 mg	04 Aug, 2008	16	11 Dec, 2013	18 Jul, 2014	Eligible
40 mg	10 May, 2012	1	11 Dec, 2013	18 Jul, 2014	Eligible

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription
EQ 60MG BASE	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription
EQ 30MG BASE	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription

CYMBALTA family patents

4. Evista patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458811	LILLY	Benzothiophenes formulations containing same and methods	Mar, 2017 (7 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE38968	LILLY	Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride	Jul, 2012 (11 years ago)
US5457117	LILLY	Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride	Jul, 2012 (11 years ago)
US6906086	LILLY	Methods for inhibiting bone loss	Jul, 2012 (11 years ago)
USRE39049	LILLY	Methods for inhibiting bone loss	Jul, 2012 (11 years ago)
US5393763	LILLY	Methods for inhibiting bone loss	Jul, 2012 (11 years ago)
US5811120	LILLY	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation	Mar, 2014 (10 years ago)
USRE39050	LILLY	Methods of use for inhibiting bone loss and lowering serum cholesterol	Mar, 2014 (10 years ago)
US5972383	LILLY	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation	Mar, 2014 (10 years ago)
US5478847	LILLY	Methods of use for inhibiting bone loss and lowering serum cholesterol	Mar, 2014 (10 years ago)
US8030330	LILLY	Benzothiophenes, formulations containing same, and methods	Mar, 2017 (7 years ago)
US6797719	LILLY	Benzothiophenes, formulations containing same, and methods	Mar, 2017 (7 years ago)
US6894064	LILLY	Benzothiophenes, formulations containing same, and methods	Mar, 2017 (7 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Sep 13, 2014

Drugs and Companies using RALOXIFENE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 1997

Treatment: Prevention of osteoporosis in postmenopausal women; Use for inhibiting bone resorption; Treatment or prevention of osteoporosis; Use for prevention of breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription

EVISTA family patents

5. Forteo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770623	LILLY	Stabilized teriparatide solutions	Dec, 2018 (5 years ago)
US7144861	LILLY	Stabilized teriparatide solutions	Dec, 2018 (5 years ago)
US7550434	LILLY	Stabilized teriparatide solutions	Dec, 2018 (5 years ago)
US7351414	LILLY	Method of reducing the risk of bone fracture	Aug, 2019 (4 years ago)
US6977077	LILLY	Method of increasing bone toughness and stiffness and reducing fractures	Aug, 2019 (4 years ago)
US7163684	LILLY	Method of increasing bone toughness and stiffness and reducing fractures	Aug, 2019 (4 years ago)
US7517334	LILLY	Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose	Mar, 2025 (11 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-302)	Nov 16, 2023
New Indication(I-602)	Jul 22, 2012

Drugs and Companies using TERIPARATIDE ingredient

Market Authorisation Date: 25 June, 2008

Treatment: A method of treating osteoporosis; Method for the treatment of a woman with osteoporosis and at risk for bone fracture; Method of treating osteoporosis in a post-menopausal woman at risk for fracture

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mcg/mL, 2.4 mL prefilled Pen	27 Jul, 2015	1		25 Mar, 2025

Strength	Dosage	Availability
0.75MG/3ML (0.25MG/ML)	SOLUTION;SUBCUTANEOUS	Discontinued
0.6MG/2.4ML (0.25MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

FORTEO family patents

6. Gemzar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5464826	LILLY	Method of treating tumors in mammals with 2',2'-difluoronucleosides	Nov, 2012 (11 years ago)
US5464826 (Pediatric)	LILLY	Method of treating tumors in mammals with 2',2'-difluoronucleosides	May, 2013 (10 years ago)

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 1996

Treatment: Method of treating susceptible neoplasms in mammals

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg/vial	01 Nov, 2005	1	18 Dec, 2008	07 Nov, 2012	Eligible
1g/vial	14 Nov, 2005	1	25 Jan, 2011	07 Nov, 2012	Eligible

Strength	Dosage	Availability
EQ 200MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued

GEMZAR family patents

7. Humalog patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
NR(NR)	Oct 12, 2015

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 15 November, 2019

Treatment: Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
100 UNITS/ML	INJECTABLE;INJECTION	Prescription

HUMALOG family patents

8. Humalog Kwikpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
NR(NR)	Oct 12, 2015

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 15 November, 2019

Treatment: Use for the treatment of hyperglycemia; Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
100 UNITS/ML	INJECTABLE;INJECTION	Prescription

HUMALOG KWIKPEN family patents

9. Humalog Mix 50/50 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5461031	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)
US5747642	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus; Use for the treatment of hyperglycemia

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
50 UNITS/ML;50 UNITS/ML	INJECTABLE;INJECTION	Prescription

HUMALOG MIX 50/50 family patents

10. Humalog Mix 50/50 Kwikpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5747642	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)
US5461031	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus; Use for the treatment of hyperglycemia

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
50 UNITS/ML;50 UNITS/ML	INJECTABLE;INJECTION	Prescription

HUMALOG MIX 50/50 KWIKPEN family patents

11. Humalog Mix 75/25 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5747642	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)
US5461031	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus; Use for the treatment of hyperglycemia

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
75 UNITS/ML;25 UNITS/ML	INJECTABLE;INJECTION	Prescription

HUMALOG MIX 75/25 family patents

12. Humalog Mix 75/25 Kwikpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5747642	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)
US5461031	LILLY	Monomeric insulin analog formulations	Jun, 2014 (9 years ago)
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus; Use for the treatment of hyperglycemia

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
75 UNITS/ML;25 UNITS/ML	INJECTABLE;INJECTION	Prescription

HUMALOG MIX 75/25 KWIKPEN family patents

13. Humalog Pen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5514646	LILLY	Insulin analogs modified at position 29 of the B chain	May, 2013 (10 years ago)
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
NR(NR)	Oct 12, 2015

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 15 November, 2019

Treatment: Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
100 UNITS/ML	INJECTABLE;INJECTION	Discontinued

HUMALOG PEN family patents

14. Humulin 70/30 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drugs and Companies using INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN ingredient

Market Authorisation Date: 25 April, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
30 UNITS/ML;70 UNITS/ML	INJECTABLE;INJECTION	Over the counter

HUMULIN 70/30 family patents

15. Humulin 70/30 Pen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drugs and Companies using INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN ingredient

Market Authorisation Date: 25 April, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
30 UNITS/ML;70 UNITS/ML	INJECTABLE;INJECTION	Over the counter

HUMULIN 70/30 PEN family patents

16. Humulin N patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drugs and Companies using INSULIN SUSP ISOPHANE RECOMBINANT HUMAN ingredient

Market Authorisation Date: 28 October, 1982

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
100 UNITS/ML	INJECTABLE;INJECTION	Over the counter

HUMULIN N family patents

17. Humulin R patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291132	LILLY	Medication dispensing apparatus with triple screw threads for mechanical advantage	Aug, 2024 (3 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
NR(NR)	Mar 25, 2014

Drugs and Companies using INSULIN HUMAN ingredient

Market Authorisation Date: 29 December, 2015

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

HUMULIN R family patents

18. Prozac Weekly patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39030	LILLY	Fluoxetine enteric pellets and methods for their preparation and use	May, 2017 (6 years ago)
US5985322	LILLY	Method for the treatment of CNS disorders	May, 2017 (6 years ago)
US5910319	LILLY	Fluoxetine enteric pellets and methods for their preparation and use	May, 2017 (6 years ago)
US5985322 (Pediatric)	LILLY	Method for the treatment of CNS disorders	Nov, 2017 (6 years ago)
US5910319 (Pediatric)	LILLY	Fluoxetine enteric pellets and methods for their preparation and use	Nov, 2017 (6 years ago)

Drugs and Companies using FLUOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 February, 2001

Treatment: Method of treating people suffering from depression; Method of treating people suffering from depression without an increase in nausea

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

PROZAC WEEKLY family patents

19. Strattera patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5658590	LILLY	Treatment of attention-deficit/hyperactivity disorder	Nov, 2016 (7 years ago)
US5658590 (Pediatric)	LILLY	Treatment of attention-deficit/hyperactivity disorder	May, 2017 (6 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-78)	Jul 23, 2011

Drugs and Companies using ATOMOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 November, 2002

Treatment: Treatment of attention-deficit hyperactivity disorder

Dosage: CAPSULE;ORAL

STRATTERA family patents

20. Symbyax patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5945416	LILLY	Method for treating pain	Mar, 2017 (7 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6960577	LILLY	Combination therapy for treatment of refractory depression	Nov, 2017 (6 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-593)	Mar 19, 2012
M(M-142)	Oct 10, 2017
New Patient Population(NPP)	Jul 26, 2016

Drugs and Companies using FLUOXETINE HYDROCHLORIDE; OLANZAPINE ingredient

Market Authorisation Date: 09 April, 2007

Treatment: Symbyax is indicated for the acute treatment of treatment resistant depression in adults

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
40MG	CAPSULE;ORAL	Prescription
25MG	CAPSULE;ORAL	Prescription
10MG	CAPSULE;ORAL	Prescription
18MG	CAPSULE;ORAL	Prescription
5MG	CAPSULE;ORAL	Discontinued
100MG	CAPSULE;ORAL	Prescription
80MG	CAPSULE;ORAL	Prescription
60MG	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
EQ 25MG BASE;EQ 12MG BASE	CAPSULE;ORAL	Prescription
EQ 50MG BASE;EQ 6MG BASE	CAPSULE;ORAL	Prescription
EQ 50MG BASE;EQ 12MG BASE	CAPSULE;ORAL	Prescription
EQ 25MG BASE;EQ 6MG BASE	CAPSULE;ORAL	Prescription
EQ 25MG BASE;EQ 3MG BASE	CAPSULE;ORAL	Prescription

Pharsight

Lilly patents expiration

1. Alimta patents expiration

ALIMTA family patents

2. Cialis patents expiration

CIALIS family patents

3. Cymbalta patents expiration

CYMBALTA family patents

4. Evista patents expiration

EVISTA family patents

5. Forteo patents expiration

FORTEO family patents

6. Gemzar patents expiration

GEMZAR family patents

7. Humalog patents expiration

HUMALOG family patents

8. Humalog Kwikpen patents expiration

HUMALOG KWIKPEN family patents

9. Humalog Mix 50/50 patents expiration

HUMALOG MIX 50/50 family patents

10. Humalog Mix 50/50 Kwikpen patents expiration

HUMALOG MIX 50/50 KWIKPEN family patents

11. Humalog Mix 75/25 patents expiration

HUMALOG MIX 75/25 family patents

12. Humalog Mix 75/25 Kwikpen patents expiration

HUMALOG MIX 75/25 KWIKPEN family patents

13. Humalog Pen patents expiration

HUMALOG PEN family patents

14. Humulin 70/30 patents expiration

HUMULIN 70/30 family patents

15. Humulin 70/30 Pen patents expiration

HUMULIN 70/30 PEN family patents

16. Humulin N patents expiration

HUMULIN N family patents

17. Humulin R patents expiration

HUMULIN R family patents

18. Prozac Weekly patents expiration

PROZAC WEEKLY family patents

19. Strattera patents expiration

STRATTERA family patents

20. Symbyax patents expiration

SYMBYAX family patents

Related content